NUTRA PHARMA CORP (NPHC)
Q2-CY2026Q1-CY2026Q4-CY2025Q3-CY2025Q2-CY2025Q1-CY2025Q4-CY2024Q3-CY2024Q2-CY2024Q1-CY2024Q4-CY2023Q3-CY2023Q2-CY2023Q1-CY2023Q4-CY2022Q3-CY2022Q2-CY2022Q1-CY2022Q4-CY2021Q3-CY2021Q2-CY2021Q1-CY2021Q4-CY2020Q3-CY2020Q2-CY2020Q1-CY2020Q4-CY2019Q3-CY2019Q2-CY2019Q1-CY2019Q4-CY2018Q3-CY2018Q2-CY2018Q1-CY2018Q4-CY2017Q3-CY2017Q2-CY2017Q1-CY2017Q4-CY2016Q3-CY2016Q2-CY2016Q1-CY2016Q4-CY2015Q3-CY2015Q2-CY2015Q1-CY2015Q4-CY2014Q3-CY2014Q2-CY2014
Balance Sheet Date2026-Mar-312025-Dec-312025-Sep-302025-Jun-302025-Mar-312024-Dec-312024-Sep-302024-Jun-302024-Mar-312023-Dec-312023-Sep-302023-Jun-302023-Mar-312022-Dec-312021-Mar-312020-Dec-312020-Sep-302020-Jun-302020-Mar-312019-Dec-312019-Sep-302019-Jun-302019-Mar-312018-Dec-312018-Sep-302018-Jun-302018-Mar-312017-Dec-312017-Sep-302017-Jun-302017-Mar-312016-Dec-312016-Sep-302016-Jun-302016-Mar-312015-Dec-312015-Sep-302015-Jun-302015-Mar-312014-Dec-312014-Sep-302014-Jun-30
Fiscal PeriodQ1-FY2026Q4-FY2025Q3-FY2025Q2-FY2025Q1-FY2025Q4-FY2024Q3-FY2024Q2-FY2024Q1-FY2024Q4-FY2023Q3-FY2023Q2-FY2023Q1-FY2023Q4-FY2022Q1-FY2021Q4-FY2020Q3-FY2020Q2-FY2020Q1-FY2020Q4-FY2019Q3-FY2019Q2-FY2019Q1-FY2019Q4-FY2018Q3-FY2018Q2-FY2018Q1-FY2018Q4-FY2017Q3-FY2017Q2-FY2017Q1-FY2017Q4-FY2016Q3-FY2016Q2-FY2016Q1-FY2016Q4-FY2015Q3-FY2015Q2-FY2015Q1-FY2015Q4-FY2014Q3-FY2014Q2-FY2014
Operating Cash Flow(327,791$)(219,818$)(250,770$)(288,370$)(405,006$)(178,210$)19,073$(93,623$)(171,199$)(186,229$)(84,191$)(186,841$)(92,775$)(54,032$)(165,341$)(284,825$)(258,234$)(594,333$)(352,823$)(137,054$)(172,654$)(215,555$)(308,721$)(151,235$)(192,199$)(91,504$)(136,047$)(162,931$)(352,657$)(348,314$)(226,387$)(244,704$)(295,772$)(371,484$)(388,348$)(419,275$)(283,141$)(265,734$)(190,382$)(208,437$)(502,395$)(116,974$)(57,402$)(22,122$)21,937$
Investing Cash Flow0$0$(25,000$)(26,052$)8,300$34,000$83,649$33,516$(9,810$)10,000$51,500$48,299$(10,500$)(61,993$)(38,450$)(2,470$)0$0$0$(718$)(1,381$)
Purchases of Property and Equipment0$0$0$26,052$0$0$0$57,993$9,950$2,470$0$0$0$718$1,381$
Financing Cash Flow337,454$228,396$175,304$378,596$408,454$206,357$(53,073$)94,623$171,199$102,580$50,675$196,651$82,775$2,532$106,594$298,834$236,256$634,533$358,728$79,184$230,524$215,555$308,721$37,522$305,912$91,504$121,888$154,111$373,700$350,250$235,500$239,174$282,977$358,566$401,745$432,875$287,513$262,100$192,990$93,817$621,187$102,272$46,513$26,115$11,677$
End Cash Position12,181$36,447$0$15,530$27,800$43,976$
Exchange Rate Effect
Dividends Paid
Unlevered Free Cash Flow(327,791$)(219,818$)(250,770$)(288,370$)(431,058$)(178,210$)19,073$(93,623$)(171,199$)(186,229$)(84,191$)(186,841$)(92,775$)(54,032$)(165,341$)(284,825$)(316,227$)(604,283$)(352,823$)(137,054$)(172,654$)(215,555$)(308,721$)(151,235$)(192,199$)(91,504$)(136,047$)(162,931$)(352,657$)(348,314$)(226,387$)(244,704$)(295,772$)(371,484$)(390,818$)(419,275$)(283,141$)(265,734$)(190,382$)(208,437$)(502,395$)(117,692$)(58,783$)(22,122$)21,937$